BR112013012627A2 - proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição - Google Patents

proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição

Info

Publication number
BR112013012627A2
BR112013012627A2 BR112013012627A BR112013012627A BR112013012627A2 BR 112013012627 A2 BR112013012627 A2 BR 112013012627A2 BR 112013012627 A BR112013012627 A BR 112013012627A BR 112013012627 A BR112013012627 A BR 112013012627A BR 112013012627 A2 BR112013012627 A2 BR 112013012627A2
Authority
BR
Brazil
Prior art keywords
composition
polynucleotide
flow meter
fuel flow
antigen binding
Prior art date
Application number
BR112013012627A
Other languages
English (en)
Inventor
Chun-Wa Chung
Garcy Peter Bembridge
Ian Kirby
Maria Feeney
Ruth Mcadam
Susannah Karen Ford
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45001764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013012627(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112013012627A2 publication Critical patent/BR112013012627A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Volume Flow (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, método de tratar um paciente humano afetado com um distúrbio ou doença imflamatória, e uso da composição. métodos e sistemas para detectar fraude causada por adulteração de um medidor de fluxo de combustível. em uma forma de realização, o método compreende prover um medidor de fluxo de combustível para medir o fluxo de combustível líquido. o medidor de fluxo tem pelo menos um eixo suportando um rotor. o método compreende adicionalmente prover o medidor de fluxo com um sensor de deslocamento rotativo. também, o método compreende medir uma primeira posição angular do eixo no término de uma primeira transação de abastecimento, e medir uma segunda posição angular do eixo no início de uma segunda transação de abastecimento. finalmente, o método compreende comparar dados indicativos das primeiras e segunda posições angulares do eixo para determinar se ocorreu fraude.
BR112013012627A 2010-11-23 2011-11-21 proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição BR112013012627A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41649510P 2010-11-23 2010-11-23
PCT/EP2011/070604 WO2012069433A2 (en) 2010-11-23 2011-11-21 Antigen binding proteins

Publications (1)

Publication Number Publication Date
BR112013012627A2 true BR112013012627A2 (pt) 2016-10-04

Family

ID=45001764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012627A BR112013012627A2 (pt) 2010-11-23 2011-11-21 proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição

Country Status (38)

Country Link
US (4) US8916695B2 (pt)
EP (3) EP3369744A1 (pt)
JP (2) JP6351973B2 (pt)
KR (2) KR20130119948A (pt)
CN (1) CN103328508B (pt)
AR (1) AR083937A1 (pt)
AU (1) AU2011333878B2 (pt)
BR (1) BR112013012627A2 (pt)
CA (1) CA2818534A1 (pt)
CL (1) CL2013001466A1 (pt)
CO (1) CO6801627A2 (pt)
CY (1) CY1120448T1 (pt)
DK (1) DK2643352T3 (pt)
DO (1) DOP2013000113A (pt)
EA (1) EA027256B1 (pt)
ES (1) ES2681949T3 (pt)
HR (1) HRP20181092T1 (pt)
HU (1) HUE039412T2 (pt)
IL (1) IL226157B (pt)
JO (1) JO3455B1 (pt)
LT (1) LT2643352T (pt)
MA (1) MA34742B1 (pt)
ME (1) ME03069B (pt)
MX (1) MX351887B (pt)
MY (1) MY170404A (pt)
NZ (1) NZ610464A (pt)
PE (1) PE20140519A1 (pt)
PL (1) PL2643352T3 (pt)
PT (1) PT2643352T (pt)
RS (1) RS57502B1 (pt)
SG (2) SG190232A1 (pt)
SI (1) SI2643352T1 (pt)
TR (1) TR201810773T4 (pt)
TW (1) TWI504609B (pt)
UA (1) UA111954C2 (pt)
UY (1) UY33743A (pt)
WO (1) WO2012069433A2 (pt)
ZA (1) ZA201303541B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261223B (zh) 2010-10-13 2017-03-29 詹森生物科技公司 人制瘤素m抗体及使用方法
TR201810773T4 (tr) 2010-11-23 2018-08-27 Glaxo Group Ltd Onkostatin m?ye (osm) antijen bağlayıcı proteinler.
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US20170327573A1 (en) 2014-09-24 2017-11-16 Universitá Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
EP3974450A3 (en) 2015-01-29 2022-06-22 Oxford University Innovation Limited Biomarker
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ATE158615T1 (de) 1990-03-20 1997-10-15 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
PL199659B1 (pl) 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
DE60037648T2 (de) * 2000-04-21 2010-06-17 Conaris Research Institute Ag Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
IL166244A0 (en) * 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
WO2005003156A1 (en) 2003-07-04 2005-01-13 Affibody Ab Polypeptides having binding affinity for her2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
PE20050925A1 (es) * 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
GB0407197D0 (en) * 2004-03-30 2004-05-05 Glaxo Group Ltd Immunoglobulins
SI1730191T1 (sl) * 2004-03-30 2011-11-30 Glaxo Group Ltd Imunoglobulin-vezavni hOSM
CA2573745A1 (en) 2004-07-21 2007-01-12 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
KR101318611B1 (ko) 2005-07-22 2013-11-13 교와 핫꼬 기린 가부시키가이샤 유전자 재조합 항체 조성물
ES2514495T3 (es) * 2006-05-25 2014-10-28 Glaxo Group Limited Anticuerpos humanizados modificados anti-interleucina-18
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
WO2010056893A1 (en) * 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
CN103261223B (zh) * 2010-10-13 2017-03-29 詹森生物科技公司 人制瘤素m抗体及使用方法
TR201810773T4 (tr) 2010-11-23 2018-08-27 Glaxo Group Ltd Onkostatin m?ye (osm) antijen bağlayıcı proteinler.

Also Published As

Publication number Publication date
EP2643352A2 (en) 2013-10-02
US20170152312A1 (en) 2017-06-01
PL2643352T3 (pl) 2018-10-31
HRP20181092T1 (hr) 2018-09-21
AU2011333878B2 (en) 2016-01-14
US20150064201A1 (en) 2015-03-05
TW201235358A (en) 2012-09-01
CO6801627A2 (es) 2013-11-29
HUE039412T2 (hu) 2018-12-28
DOP2013000113A (es) 2013-12-15
MX351887B (es) 2017-11-01
CN103328508A (zh) 2013-09-25
TWI504609B (zh) 2015-10-21
JO3455B1 (ar) 2020-07-05
CA2818534A1 (en) 2012-05-31
TR201810773T4 (tr) 2018-08-27
CL2013001466A1 (es) 2014-06-27
UA111954C2 (uk) 2016-07-11
KR20130119948A (ko) 2013-11-01
UY33743A (es) 2012-06-29
KR20180110199A (ko) 2018-10-08
AR083937A1 (es) 2013-04-10
JP2017078072A (ja) 2017-04-27
WO2012069433A3 (en) 2012-08-09
MX2013005843A (es) 2013-07-05
EP3211009A1 (en) 2017-08-30
ZA201303541B (en) 2014-11-26
SG190232A1 (en) 2013-06-28
MY170404A (en) 2019-07-27
PT2643352T (pt) 2018-08-01
SG10201500388PA (en) 2015-03-30
US10808029B2 (en) 2020-10-20
IL226157A0 (en) 2013-06-27
US8916695B2 (en) 2014-12-23
PE20140519A1 (es) 2014-04-30
MA34742B1 (fr) 2013-12-03
AU2011333878A1 (en) 2013-05-09
CN103328508B (zh) 2015-12-16
NZ610464A (en) 2015-02-27
EA027256B1 (ru) 2017-07-31
JP6351973B2 (ja) 2018-07-04
RS57502B1 (sr) 2018-10-31
LT2643352T (lt) 2018-08-10
WO2012069433A2 (en) 2012-05-31
ES2681949T3 (es) 2018-09-17
US20130251724A1 (en) 2013-09-26
JP2014507373A (ja) 2014-03-27
KR101947356B1 (ko) 2019-02-12
CY1120448T1 (el) 2019-07-10
IL226157B (en) 2020-10-29
EP3369744A1 (en) 2018-09-05
ME03069B (me) 2019-01-20
SI2643352T1 (sl) 2018-12-31
US20210017270A1 (en) 2021-01-21
EP2643352B1 (en) 2018-05-02
US9605063B2 (en) 2017-03-28
DK2643352T3 (en) 2018-07-30
EA201390537A1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
BR112013012627A2 (pt) proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição
WO2012076666A3 (en) Fuel dispenser flow meter sensor fraud prevention
BR112013026975A2 (pt) unidade de medidor de fluxo de combustível
BRPI0822593B8 (pt) Método para detectar, de modo audível, uma mudança de estado de fluxo de fluido e corrigir uma medição de um medidor de fluxo em uma tubulação de medidor de fluxo, e, sistema para melhorar a precisão de um medidor de fluxo
Breyer et al. Better nephrology for mice—and man
BR112012020270A2 (pt) sistema e método para administrar medicamentos com base em valores de urina.
EP2549237A3 (en) High-resolution non-contacting multi-turn sensing systems and methods
BR112015005052B8 (pt) Sistema de medição de fluxo ultrassônico, e, método para compensação de temperatura em medição ultrassônica
WO2010092544A3 (en) Flow meter
BR112014006855B8 (pt) Sistema de medição de fluxo ultrassônico, método para medir fluxo de fluido, e, mídia legível por computador
BRPI0909791A2 (pt) Cartucho, dispositivo sensor e método para detecção de componentes alvo em uma amostra líquida, e, uso do cartucho ou do dispositivo sensor.
NZ710981A (en) Fluid flow meter
GB201302242D0 (en) Apparatus adapted to provide an indication of an angular position of an input member over multiple turns
BR112015029794A2 (pt) disposição para a detecção de um volume de distribuição, dispositivo, sistema de extração, métodos para a detecção de um volume de distribuição e para a medição de uma usina de proteção
BR112014008952A2 (pt) sensor para gás solúvel em fluido
BR112015001102A2 (pt) método de detecção de câncer, droga ou kit e método de seleção de droga terapêutica
EP3144670A3 (en) Anticancer agent sensitivity-determining marker
EA201591780A1 (ru) Обнаружение и предотвращение мошенничества при использовании расходомера топливораздаточной колонки
BR112012024619A2 (pt) sistema e método para avaliação de candidato a medicamento anticancer
WO2010080341A3 (en) A method for field-measuring fluid flow meters
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
Li et al. The benefit of a glucose-sparing PD therapy on glycemic control measured by serum fructosamine in diabetic patients in a randomized, controlled trial (IMPENDIA)
BR112014024911B8 (pt) Sistema de medição de fluxo ultrassônico, e, método para a substituição do medidor de fluxo
UA38918U (ru) Топливная система двигателя с участком для измерения расхода топлива
Han The human capital loss of air pollution in cities, China

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]